Acute ST-segment elevation myocardial infarction (STEMI) is the one of the most dangerous types of heart attack where there is a serious blockage in one of the major coronary arteries in the heart. The "ST" reference identifies the section of electrocardiogram (ECG) (between the S and T segments on the ECG waveform readout) where there is an abnormality shown as an elevated waveform on the 12-lead ECG.

Minimally invasive, cath lab-based primary percutaneous coronary intervention (PCI) is the preferred treatment for STEMI. This includes use of balloon angioplasty and coornary stent placement to prop open the artery. Centers without a cath lab will usually start an an IV bag with thrombolytic agents to begin dissolving the clot causing the heart attack. This includes use of aspirin and heparin, and in some cases, antiplatelet agents such as ticagrelor. This is usually followed by transport of the patient to the closest hospital with a cath lab. 

The conventional standard of care works on the idea that the longer it takes to reopen a STEMI lesion to restore blood flow to the heart muscle, the more damage will likely occur. Lack of oxygen can cause an infarct, where part of the heart muscle dies. This can lead later to heart failure. There is a direct relationship between the length of time a coronary artery is blocked, the amount of permanent damage to the heart, and odds of survival or full recovery. 

This has led to the term “time is muscle” and great emphasis has been placed on reducing door-to-balloon (D2B) times at hospitals with cath labs. D2B refers to the amount of time it takes between the patient coming through the door of the hospital to the time an angioplasty balloon can be used to reopen the artery. The national standard is to achieve D2B times of 90 minutes or less. Some centers count D2B time from the arrival of emergency medical services (EMS) by the patient's side to angioplasty. 

Hospitals that work to reduce door-to-balloon times are often most successful if they create a STEMI alert system. This requires close coordination between EMS, the hospital emergency department (ED, or emergency room, ER), cath lab staff and the interventional cardiologists. When paramedics detect a suspected STEMI patient with their defibrillator-monitors, a call is immediately made to the ED to start a STEMI alert, or STEMI code. The ED doctor who received the pre-hospital ECG confirms the STEMI, and sends it on to the interventional cardiologist on call for further validation. During daytime hours the cath lab staff prepare a room for the patient, or after-hours are called in to prep the cath lab. The heart team meets the patient at the ambulance dock and transports them directly to the cath lab to save time. 

Links to more STEMI Information:

Why STEMI Heart Attacks are so Deadly

ECG in STEMI - Importance and Challenges

Acute Myocardial Infarction ST Elevation (STEMI)

What is a STEMI? 


News | Cardiovascular Clinical Studies

April 8, 2024 — Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly ...

Home April 08, 2024
News | STEMI

February 27, 2023 — CÚRAM SFI Research Centre for Medical Devices researchers have published in Nature Communications a ...

Home February 27, 2023
News | Cardiovascular Business

December 22, 2022 — Johnson & Johnson today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now ...

Home December 22, 2022
Johnson & Johnson to Acquire Abiomed
Feature | Cardiovascular Business

November 1, 2022 — Johnson & Johnson and Abiomed, a world leader in breakthrough heart, lung and kidney support ...

Home November 01, 2022
News | STEMI

September 13, 2022 — ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related ...

Home September 13, 2022
News | Womens Cardiovascular Health

July 1, 2022 — Despite overall improvements to care for a heart attack, women are less likely to receive timely ...

Home July 01, 2022
News | Womens Cardiovascular Health

June 23, 2022 — Despite overall improvements to care for a heart attackwomen are less likely to receive timely ...

Home June 23, 2022
News | Cardiogenic Shock

June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin ...

Home June 01, 2022
News | STEMI

May 20, 2022 — Results from a retrospective analysis reveal significantly higher mortality rates for low-income ...

Home May 20, 2022
Subscribe Now